Ranibizumab & Aflibercept- two new drugs for diabetic retinopathy in patients with diabetic macular edema.

The U.S. Food and Drug Administration approved two new drugs for treatment of  diabetic retinopathy in patients with diabetic macular edema.

Diabetic retinopathy is the most common ocular manifestation of  diabetes and is a leading cause of blindness.

Ranizumab & aflibercept are monoclonal antibodies which act as  a vascular endothelial growth factor (VEGF) inhibitors,prevent angiogenesis.

It is approved for treatment of :

1) neovascular (wet) age-related macular degeneration.

2) Macular edema due to retinal vein occlusion.

3) Diabetic macular edema

4) Diabetic retinopathy due to macular edema


It is given as  intravitreal injection.

Patient should be monitored after injection for a week.

Adverse drug reactions observed most commonly are  conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.


Endophthalmitis and retinal detachments may occur

Increases in intraocular pressure have been noted within 60 minutes of intravitreal injection.

A potential risk of arterial thromboembolic event after injection may occur.